Predict your next investment

HEALTHCARE | Biotechnology
creativepeptides.se

See what CB Insights has to offer

Founded Year

1996

Stage

Acquired | Acquired

About Creative Peptides

Developer of biopharmaceutical drugs to treat long-term complications of type 1 diabetes. The company develops biopharmaceutical drugs based on C-peptide and it is focused mainly on type 1 diabetes neuropathy.

Creative Peptides Headquarter Location

Fogdevreten 2

Stockholm, 171 77,

Sweden

46 8 524 84 48 0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Creative Peptides

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Creative Peptides is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,734 items

Creative Peptides Patents

Creative Peptides has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Designer drugs
  • Euphoriants
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/3/2018

4/13/2021

HIV/AIDS, Immunology, Clusters of differentiation, Vaccines, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/3/2018

00/00/0000

Grant Date

4/13/2021

00/00/0000

Title

Subscribe to see more

Related Topics

HIV/AIDS, Immunology, Clusters of differentiation, Vaccines, Immune system

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.